- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04284839
Den direkte orale antikoagulasjonsforsøket versus warfarin etter hjertekirurgi (DANCE)
The DANCE Trial is a multi-centre, randomized controlled trial comparing the safety of direct oral anticoagulants (DOAC) versus vitamin K antagonists (VKA) in the early period (30 days) after cardiac surgery in patients with atrial fibrillation requiring oral anticoagulation.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
Approximately 36,000 Canadian adults undergo cardiac surgery annually. Of these patients, about 10% have a prior history of atrial fibrillation (AF). In the early post-operative period after cardiac surgery, 30-60% of patients develop AF and, by the time of discharge, 32% of patients who underwent cardiac surgery have an indication for oral anticoagulation (OAC). AF is associated with a significantly higher risk of stroke, even when transient, and OAC is the standard for thromboembolic prevention in these patients. In the post-operative period, the balance of benefits and risks of OAC may differ and the safest and most effective OAC in that patient population is uncertain.
Vitamin K antagonists (VKAs), such as warfarin or coumadin, are the most used anticoagulants after cardiac surgery. In the Left Atrial Appendage Occlusion Study (LAAOS) III that recruited 4811 patients from 105 centres in 27 countries, 77% of patients with AF on OAC were discharged on a VKA after cardiac surgery. Among patients taking a DOAC preoperatively, 55% were switched to a VKA after surgery. Over the first post-operative year, most of those patients were gradually transitioned back to a DOAC. Although effective, the use of VKAs is limited by a narrow therapeutic index requiring frequent international normalized ratio (INR) measurements to ensure appropriate levels of anticoagulation. This key limitation leads to non-compliance and discontinuation. In addition, in the first 3 months after cardiac surgery, time in the therapeutic range is low, even with close monitoring by experienced prescribers.
In the last decade, DOACs - inhibitors of factor Xa or thrombin- have become broadly used in patients with AF. Treatment with a DOAC in patients with AF has been demonstrated to yield a lower risk of stroke or systemic embolism and a similar risk of major bleeding when compared to VKAs during long-term follow-up. Moreover, DOACs are more convenient for both patients and clinicians. They have a rapid onset of effect, fixed dosage that obviates the need for regular monitoring, and few interactions with food and other medications. In the postoperative setting, DOACs may also lead to shorter length of stay and reduced costs.
The purpose of this study is to establish whether DOACs are as safe as VKAs in the first few weeks after heart surgery. The results of this study will impact the treatment of hundreds of thousands of patients in the world every year.
A subset of 910 DANCE participants with a recent bioprosthetic aortic and/or mitral valve replacement will be enrolled in the SUNDANCE substudy (Subclinical valve thrombosis in patients with surgical bioprosthetic valve replacement: An imaging substudy of the DANCE trial). SUNDANCE will examine the effects of DOACs versus VKAs on subclinical valve thrombosis and bioprosthetic valve function by conducting computed tomography (CT) scans and echocardiograms at 60 to 90 days after randomization.
Studietype
Registrering (Antatt)
Fase
- Fase 3
Kontakter og plasseringer
Studiekontakt
- Navn: Richard Whitlock, MD, PhD
- Telefonnummer: 40306 905-527-4322
- E-post: richard.whitlock@phri.ca
Studer Kontakt Backup
- Navn: Emilie Belley-Cote, MD, MSc
- Telefonnummer: 40306 905-527-4322
- E-post: emilie.belley-cote@phri.ca
Studiesteder
-
-
Victoria
-
Fitzroy, Victoria, Australia, 3065
- Rekruttering
- St Vincent's Hospital Melbourne
-
Ta kontakt med:
- Andrew Newcomb, MD
-
Hovedetterforsker:
- Andrew Newcomb, MD
-
Parkville, Victoria, Australia, 3050
- Har ikke rekruttert ennå
- Royal Melbourne Hospital, University of Melbourne
-
Ta kontakt med:
- Alistair Royse, MD
-
Hovedetterforsker:
- Alistair Royse, MD
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 2C8
- Rekruttering
- University of Alberta Hospital
-
Hovedetterforsker:
- Steven Meyer, MD
-
Ta kontakt med:
- Steven Meyer, MD
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6T 1Z3
- Rekruttering
- University of British Columbia
-
Hovedetterforsker:
- Erica Wang, PharmD
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R2H 2A6
- Rekruttering
- St. Boniface Hospital
-
Hovedetterforsker:
- Michael Yamashita, MD
-
Ta kontakt med:
- Michael Yamashita, MD
-
-
New Brunswick
-
Saint John, New Brunswick, Canada, E2L4L2
- Aktiv, ikke rekrutterende
- Saint John Regional Hospital
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Canada, A1B 3V6
- Rekruttering
- Health Science Centre
-
Hovedetterforsker:
- Hasib Hanif, MD
-
-
Ontario
-
Greater Sudbury, Ontario, Canada, P3E 5J1
- Rekruttering
- Health Sciences North Research Institute
-
Hovedetterforsker:
- Bindu Bittira, MD
-
Hamilton, Ontario, Canada, L8L 2X2
- Rekruttering
- Hamilton General Hospital
-
Ta kontakt med:
- Emilie Belley-Cote, MD, MSc
- Telefonnummer: 40306 905-527-4322
- E-post: emilie.belley-cote@phri.ca
-
Toronto, Ontario, Canada, M5G 2C4
- Rekruttering
- Toronto General Hospital
-
Ta kontakt med:
- Vivek Rao, MD
-
Hovedetterforsker:
- Vivek Rao, MD
-
Toronto, Ontario, Canada, M4N 3M5
- Rekruttering
- Sunnybrook Hospital
-
Ta kontakt med:
- Stephen Fremes, MD
-
Hovedetterforsker:
- Stephen Fremes, MD
-
-
Quebec
-
Montreal, Quebec, Canada, H1T 1C8
- Rekruttering
- Montreal Heart Institute
-
Ta kontakt med:
- Philippe Demers, MD
-
Hovedetterforsker:
- Philippe Demers, MD
-
Montreal, Quebec, Canada, H4J1C5
- Rekruttering
- Hôpital Sacré-Coeur de Montréal
-
Hovedetterforsker:
- Hugues Jeanmart, MD
-
Ta kontakt med:
- Hugues Jeanmart, MD
-
Québec, Quebec, Canada, G1V 4G5
- Rekruttering
- IUCPQ-ULaval
-
Ta kontakt med:
- Eric Dumont, MD
-
Hovedetterforsker:
- Eric Dumont, MD
-
-
-
-
-
Bonn, Tyskland, 53127
- Aktiv, ikke rekrutterende
- University Hospital Bonn Heart Center
-
Essen, Tyskland, 45147
- Har ikke rekruttert ennå
- West-German Heart and Vascular Center, University of Duisburg-Essen
-
Ta kontakt med:
- Matthias Thielmann, MD, PhD
-
Hovedetterforsker:
- Matthias Thielmann, MD, PhD
-
Hamburg, Tyskland, 20246
- Rekruttering
- University Medical Center Hamburg-Eppendorf
-
Ta kontakt med:
- Simon Pecha, MD
-
Hovedetterforsker:
- Simon Pecha, MD
-
-
Saxony
-
Leipzig, Saxony, Tyskland, 04289
- Aktiv, ikke rekrutterende
- Heart Center Leipzig
-
-
Thuringia
-
Jena, Thuringia, Tyskland, Germany
- Rekruttering
- University Hospital Jena
-
Ta kontakt med:
- Torsten Doenst, MD, PhD
-
Hovedetterforsker:
- Torsten Doenst, MD, PhD
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Age ≥18 years at the time of enrolment,
- Open heart surgery in the last 10 days,
- Atrial fibrillation requiring anticoagulation (including pre-existing or post-operative atrial fibrillation),
- Informed consent from either the patient or a substitute decision-maker.
Exclusion Criteria:
- Mechanical valve replacement,
- Antiphospholipid syndrome (triple positive),
- Severe renal failure (Cockcroft-Gault equation; creatinine clearance <15 ml/min),
- Known significant liver disease (Child-Pugh classification B and C),
- Left ventricular thrombus,
- Ongoing bleeding, hemorrhagic disorders, or bleeding diathesis,
- Known contraindication for any DOAC or VKA,
- Women who are pregnant, breastfeeding, or of childbearing potential,
- Surgery including left ventricular assist device implantation or cardiac transplantation,
- Previously enrolled in this trial,
- Follow-up not possible,
- History of moderate or severe mitral valvular lesion (stenosis or regurgitation) that is not corrected during index cardiac surgery.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Faktoriell oppgave
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Direct Oral Anticoagulation (DOAC)
Patients in the intervention group will receive a DOAC at doses recommended for the indication, adjusted for their renal function is required. The choice of DOAC will be at the discretion of the treating physician. |
Patients will receive a DOAC at doses recommended for the indication, adjusted for their renal function is required. The choice of DOAC will be at the discretion of the treating physician.
Andre navn:
|
|
Placebo komparator: Vitamin K Antagonist
Patients in the control group will receive VKA once daily; the individual dose will be titrated to achieve a guideline-recommended INR range. |
Patients in the control group will receive VKA once daily; the individual dose will be titrated to achieve a guideline-recommended INR range.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Major Bleeding
Tidsramme: 30-Days post-randomization
|
Major bleeding at 30 days, defined as bleeding that results in death and/or symptomatic bleeding in a critical area or organ, bleeding into a surgical site requiring reoperation, bleeding leading to hospitalization (including presentation to an acute care facility without overnight stay) and/or bleeding that causes a drop in the hemoglobin level of 20g/L or more or that which requires the transfusion of ≥2 units of packed red blood cells or whole blood (as defined by the International Society of Thrombosis and Hemostasis) |
30-Days post-randomization
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Sammensatt av slag og systemisk arteriell emboli som ikke er sentralnervesystemet etter 30 og 90 dager.
Tidsramme: 30-dager og 90-dager etter randomisering
|
30-dager og 90-dager etter randomisering
|
|
Store blødninger
Tidsramme: 90 dager etter randomisering
|
90 dager etter randomisering
|
|
Pleural eller perikardiell effusjon som krever drenering
Tidsramme: 30-dager og 90-dager etter randomisering
|
30-dager og 90-dager etter randomisering
|
|
Systemisk arteriell emboli
Tidsramme: 30-dager og 90-dager etter randomisering
|
30-dager og 90-dager etter randomisering
|
|
Iskemisk hjerneslag
Tidsramme: 30-dager og 90-dager etter randomisering
|
30-dager og 90-dager etter randomisering
|
|
Dyp venetrombose
Tidsramme: 30-dager og 90-dager etter randomisering
|
30-dager og 90-dager etter randomisering
|
|
Lungeemboli
Tidsramme: 30-dager og 90-dager etter randomisering
|
30-dager og 90-dager etter randomisering
|
|
Lengde på postoperativt sykehusopphold
Tidsramme: 30-dager og 90-dager etter randomisering
|
30-dager og 90-dager etter randomisering
|
|
Dødelighet av alle årsaker
Tidsramme: 6 måneder etter randomisering
|
6 måneder etter randomisering
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Hjerteinfarkt
Tidsramme: 30-dager og 90-dager etter randomisering
|
30-dager og 90-dager etter randomisering
|
|
|
Sammenheng mellom subklinisk klaffetrombose og klinisk signifikant aortaklafftrombose, slag eller systemisk emboli
Tidsramme: 90 dager
|
90 dager
|
|
|
Minor Bleeding
Tidsramme: 30-Days and 90-Days post-randomization
|
Tertiary outcome |
30-Days and 90-Days post-randomization
|
|
All bleeding (major plus minor)
Tidsramme: 30-Days and 90-Days post-randomization
|
Tertiary outcome |
30-Days and 90-Days post-randomization
|
|
Valve Thrombosis
Tidsramme: 30-Days and 90-Days post-randomization
|
Tertiary outcome |
30-Days and 90-Days post-randomization
|
|
Hemorrhagic stroke
Tidsramme: 30-Days and 90-Days post-randomization
|
Tertiary outcome |
30-Days and 90-Days post-randomization
|
|
All Stroke
Tidsramme: 30-Days and 90-Days post-randomization
|
Tertiary outcome |
30-Days and 90-Days post-randomization
|
|
All Arterial Thrombosis/thromboembolism
Tidsramme: 30-Days and 90-Days post-randomization
|
Tertiary outcome: ischemic stroke, systemic arterial embolism, myocardial infarction, valve thrombosis |
30-Days and 90-Days post-randomization
|
|
Quality of Life - EQ-5D-5L
Tidsramme: 30-Days and 90-Days post-randomization
|
Tertiary outcome: Measured by The EQ-5D-5L Questionnaire |
30-Days and 90-Days post-randomization
|
|
Patient Satisfaction with Anticoagulant treatment
Tidsramme: 30-Days and 90-Days post-randomization
|
Tertiary outcome: Assessed by the Perception of Anticoagulant Treatment Questionnaire |
30-Days and 90-Days post-randomization
|
|
Subclinical Valve Thrombosis on CT scan
Tidsramme: 60 to 90-Days post-randomization
|
Substudy outcome |
60 to 90-Days post-randomization
|
|
Mean Aortic Valve g=Gradient on echocardiogram
Tidsramme: 60 to 90-Days post-randomization
|
Substudy outcome |
60 to 90-Days post-randomization
|
|
Aortic Valve Reintervention
Tidsramme: 60 to 90-Days post-randomization
|
Substudy outcome |
60 to 90-Days post-randomization
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Emilie Belley-Cote, MD, MSc, McMaster University
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Patologiske prosesser
- Patologiske tilstander, tegn og symptomer
- Blødning
- Svovelforbindelser
- Organiske kjemikalier
- Pyridiner
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Benzimidazoles
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ringen
- Pyraner
- Morfoliner
- Oksaziner
- Tiophener
- Kumariner
- Benzopyraner
- 4-hydroxycoumarins
- Rivaroksaban
- Dabigatran
- Warfarin
- Apixaban
- Edoxaban
Andre studie-ID-numre
- DANCE-2020
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
We will establish a plan for the full-scale study but there is no plan to make IPD available to other researchers.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .